Navigation Links
Spherix Announces Registered Direct Offering of $1.15 Million
Date:2/2/2012

BETHESDA, Md., Feb. 2, 2012 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it has entered into definitive agreements to sell $1.15 million of shares of its common stock and warrants to purchase shares of its common stock in a registered direct offering to institutional investors.  Spherix will issue an aggregate of 1,064,815 shares of common stock to the institutional investors together with warrants to purchase an additional 212,963 shares of common stock.

Each investor will receive one (1) share of common stock and a warrant to purchase 0.2 shares of common stock for a purchase price of $1.08.  The warrants have an exercise price of $1.40 per share, and are exercisable 6 months after issuance and terminate 66 months after the date of issuance.

The Company intends to use the net proceeds from the offering to continue the development of SPX-106T; for general development and commercialization efforts, including the possibility of obtaining by license or acquisition other clinical stage compounds/orphan drugs; as well as general corporate purposes.

The closing of the offering is expected to occur on February 7, 2012, or earlier, subject to customary closing conditions, at which time Spherix will receive the cash proceeds and deliver the securities.

Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), acted as the exclusive placement agent for the offering.

The common stock and warrants are being offered by Spherix pursuant to an effective
'/>"/>

SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
2. Spherix Transfers Stock Listing to Nasdaq Capital Market
3. Spherix Reports 3rd Quarter Earnings
4. Spherix Announces 2008 Financial Results
5. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
6. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
7. Spherix to Exhibit at the BIO 2009 International Convention
8. Spherix Regains Full NASDAQ Compliance
9. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
10. Spherix Announces Termination of Arla License Agreement
11. Spherix Reports Second Quarter 2009 Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... ,60s cleanup of toxic pollution in Seattle,s ... Lake Washington, ... but sometimes, at least in the case of a little fish called ... study led by researchers at Fred Hutchinson Cancer Research,Center and published online ...
... KV is Now Offering The Complete Line of All Four ... ... the 50 mg ... KVa/KVb), a fully integrated specialty pharmaceutical company that,develops, manufactures, acquires ...
... BALTIMORE, May 15 Lentigen Corporation announced today,that ... (NIH) small,business innovation research (SBIR) grants to collaborate ... its proprietary,lentiviral vector (LV) technology to the development ... medical need:, -- Melanoma, with Michael ...
Cached Biology Technology:Researchers Document Rapid, Dramatic 'Reverse Evolution' in the Threespine Stickleback Fish 2Researchers Document Rapid, Dramatic 'Reverse Evolution' in the Threespine Stickleback Fish 3Researchers Document Rapid, Dramatic 'Reverse Evolution' in the Threespine Stickleback Fish 4KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R) 2KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R) 3KV Pharmaceutical Company Announces Approval for the 50 mg Strength of Generic Version of Toprol-XL(R) 4Lentigen Corporation Receives Four Research Grants From the National Institutes of Health 2
(Date:4/20/2014)... gene expression analysis growing in importance for both ... Mellon University and the University of Maryland have ... up estimates of gene activity from RNA sequencing ... after the famously speedy fish, estimates of gene ... completed in a few minutes, with accuracy that ...
(Date:4/18/2014)... in Peru found that 28 percent of the ... falsified. Many pills released the active ingredient too ... batch had no active ingredient at all. ... the Georgia Institute of Technology developed a sophisticated ... counterfeit drugs and then characterize their chemical composition. ...
(Date:4/18/2014)... Seeds that sprout as soon as they,re planted may ... to be more careful. In the wild, a plant whose ... would risk disaster. More than just an insurance policy against ... seed dormancy has long-term advantages too: Plants whose seeds ... to more species, finds in a team of researchers working ...
Breaking Biology News(10 mins):Computational method dramatically speeds up estimates of gene expression 2Counterfeit contraceptives found in South America 2Counterfeit contraceptives found in South America 3Plants with dormant seeds give rise to more species 2
... confuse the immune system and thwarting biological defenses. ... neutralize the cancer,s chemical arsenal and boost a patient,s ... time are rarely successful. Now, researchers have developed ... of both an immune-system booster and a chemical to ...
... A new genetic mutation that causes familial amyotrophic lateral ... Lou Gehrig,s Disease, has been identified by a team ... Massachusetts Medical School (UMMS). Mutations to the profilin (PFN1) ... of nerve cell axons, is estimated to account for ...
... times more valuable while improving ecology, according to a ... the online journal PLoS ONE . By ... harmful government subsidies, and putting in place effective management ... year, rather than losing US$13 billion per year. ...
Cached Biology News:Elegant delivery 2Elegant delivery 3UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 2UMMS researchers isolate gene mutations in patients with inherited amyotrophic lateral sclerosis 3
... your samples with eArray and Agilents custom printing. ... own microarray designs that meet your specific biological ... delivery of your arrays in weeks, anywhere in ... creation application tool that enables you to design ...
... are used to study co-translational and ... events such as signal peptide cleavage, ... can be examined by the translation ... in the presence of these microsomal ...
Procollagen type I C-terminal propeptide (human, PICP)...
... Small Molecule Localization in Early Drug ... Get essential drug compound localization ... spectrometry. Protein Discoverys imaging mass spectrometry service ... them with histological images so you can ...
Biology Products: